Neoplasms

Digestive System Diseases

All Conditions

Rare Diseases

Stomach Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Stomach Diseases

Stomach Cancer

Antineoplastic Agents

All Drugs and Chemicals

Anti-Infective Agents

Etoposide

Epirubicin

Oxaliplatin

Etoposide phosphate

Enzyme Inhibitors

Anti-Bacterial Agents

Antibiotics, Antitubercular

A three-cycle neoadjuvant chemotherapy will be performed in all cases. In every cycle, oxaliplatin 150 mg, etoposide 100 mg and epirubicin 50 mg will be administered from the celiac artery on day 1. Oral S-1 120 mg per day will be given for days 1-14. The second cycle will be scheduled following a 1-week rest after the first cycle.After two courses of neoadjuvant chemotherapy, patients will be reevaluated and receive curative or palliative resection or exploratory laparotomy within 14 days after completing the second course of chemotherapy.

oxaliplatin 150 mg will be administered from the celiac artery on day 1 of every cycle in all cases

oxaliplatin

etoposide 100 mg will be administered from the celiac artery on day 1 of every cycle in all cases

etoposide

epirubicin 30 mg will be administered from the celiac artery on day 1 of every cycle in all cases

epirubicin

Oral S-1 120 mg per day will be administered on days 1-14 of every cycle in all cases

Qi He, M.D., PhD.

Xulin Wang, M.D., PhD.

Guoli Li, M.D.

Scirrhous gastric cancer, also known as linitis plastic or Borrmann type 4, is an aggressive tumor with an extremely poor prognosis. Aggressive surgical procedures and adjuvant chemotherapies have not improved the survival rate. The purpose of this study is to determine whether neoadjuvant Chemotherapy with SEEOX regimen via intra-arterial and intravenous administration are effective in the treatment of Borrmann type 4 gastric cancer.

Gastric cancer patients who diagnosed as Borrmann type 4 would be included in this study.They would receive 3 cycles of neoadjuvant chemotherapy with SEEOX regimen via combined intra-arterial and intravenous administration. The treatment schedule consisted of 3 courses (each, 2-week administration and 1-week withdrawal) of intra-arterial administration of oxaliplatin (150mg), etoposide (100mg) and epirubicin(30mg) by Seldinger method on day 1 and oral S-1(120mg) on days 1-14, followed by radical surgery.The efficacy and toxicity of SEEOX regimen would be examined.

Neoadjuvant Chemotherapy With SEEOX Regimen for Borrmann Type 4 Gastric Cancer

A Phase II Study of Neoadjuvant Chemotherapy With SEEOX Regimen Via Intra-arterial and Intravenous Administration Followed by Surgery for Borrmann Type 4 Gastric Cancer

Jinling Hospital, China

Professor

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Neoadjuvant Chemotherapy With SEEOX Regimen for Borrmann Type 4 Gastric Cancer	NCT02949258	Stomach Neoplas... Gastric Cancer	oxaliplatin etoposide epirubicin S1	30 Years - 75 Years	Jinling Hospital, China
Neoadjuvant Chemotherapy With SEEOX Regimen for Borrmann Type 4 Gastric Cancer	NCT02949258	Stomach Neoplas... Gastric Cancer	oxaliplatin etoposide epirubicin S1	30 Years - 75 Years	Jinling Hospital, China

Spots Global Cancer Trial Database for borrmann type 4